Biomarkers /
ARAF
Overview
A-Raf proto-oncogene, serine/threonine kinase (ARAF) is a gene that encodes a protein serine/threonine kinase. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
ARAF is altered in 1.44% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in ARAF are ARAF Mutation (1.09%), ARAF Loss (0.31%), ARAF Amplification (0.16%), ARAF R255fs (0.09%), and ARAF P8fs (0.04%) [3].
Clinical Trials
Significance of ARAF in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.